ibrutinib (PCI-32765)
Drug timelines are a Plus or Pro feature.
2 regulatory and trial events tracked for ibrutinib (PCI-32765), covering 2017-07-18 to 2019-03-19. Get the full timeline:
Most recent: Clinical Trial Update: A Study of the Bruton's Tyrosine Kinase Inhibitor, PCI-32765 (Ibrutinib), in Combination With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients With Newly Diagnosed Non-Germinal Center B-Cell Subtype of Diffuse Large B-Cell Lymphoma [Phase 3]